A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient
After failure of anthracycline- and platinum-based therapy, no effective therapies exist for management of metastatic triple-negative breast cancer (TNBC). We report a case of metastatic TNBC harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical car...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-02-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/443371 |
id |
doaj-b41082f220384048b3c2b19b6792dda8 |
---|---|
record_format |
Article |
spelling |
doaj-b41082f220384048b3c2b19b6792dda82020-11-24T21:31:58ZengKarger PublishersCase Reports in Oncology1662-65752016-02-019111211810.1159/000443371443371A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer PatientSiraj M. AliJessica WatsonKai WangJon H. ChungCaitlin McMahonJeffrey S. RossKarel A. DickeAfter failure of anthracycline- and platinum-based therapy, no effective therapies exist for management of metastatic triple-negative breast cancer (TNBC). We report a case of metastatic TNBC harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical care. MCL1 is an antiapoptotic gene in the BCL2 family, and MCL1 amplification is common in TNBC (at least 20%). A personalized dose-reduced regimen centered on a combination of sorafenib and vorinostat was implemented, based on preclinical evidence demonstrating treatment synergy in the setting of MCL1 amplification. Although hospice care was being considered before treatment initiation, the personalized regimen yielded 6 additional months of life for this patient. Further rigorous studies are needed to confirm that this regimen or derivatives thereof can benefit the MCL1-amplified subset of TNBC patients.http://www.karger.com/Article/FullText/443371EverolimusTriple-negative breast cancerMCL1BAP1Sorafenib |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Siraj M. Ali Jessica Watson Kai Wang Jon H. Chung Caitlin McMahon Jeffrey S. Ross Karel A. Dicke |
spellingShingle |
Siraj M. Ali Jessica Watson Kai Wang Jon H. Chung Caitlin McMahon Jeffrey S. Ross Karel A. Dicke A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient Case Reports in Oncology Everolimus Triple-negative breast cancer MCL1 BAP1 Sorafenib |
author_facet |
Siraj M. Ali Jessica Watson Kai Wang Jon H. Chung Caitlin McMahon Jeffrey S. Ross Karel A. Dicke |
author_sort |
Siraj M. Ali |
title |
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient |
title_short |
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient |
title_full |
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient |
title_fullStr |
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient |
title_full_unstemmed |
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient |
title_sort |
combination of targeted therapy with chemotherapy backbone induces response in a treatment-resistant triple-negative mcl1-amplified metastatic breast cancer patient |
publisher |
Karger Publishers |
series |
Case Reports in Oncology |
issn |
1662-6575 |
publishDate |
2016-02-01 |
description |
After failure of anthracycline- and platinum-based therapy, no effective therapies exist for management of metastatic triple-negative breast cancer (TNBC). We report a case of metastatic TNBC harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical care. MCL1 is an antiapoptotic gene in the BCL2 family, and MCL1 amplification is common in TNBC (at least 20%). A personalized dose-reduced regimen centered on a combination of sorafenib and vorinostat was implemented, based on preclinical evidence demonstrating treatment synergy in the setting of MCL1 amplification. Although hospice care was being considered before treatment initiation, the personalized regimen yielded 6 additional months of life for this patient. Further rigorous studies are needed to confirm that this regimen or derivatives thereof can benefit the MCL1-amplified subset of TNBC patients. |
topic |
Everolimus Triple-negative breast cancer MCL1 BAP1 Sorafenib |
url |
http://www.karger.com/Article/FullText/443371 |
work_keys_str_mv |
AT sirajmali acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT jessicawatson acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT kaiwang acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT jonhchung acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT caitlinmcmahon acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT jeffreysross acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT kareladicke acombinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT sirajmali combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT jessicawatson combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT kaiwang combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT jonhchung combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT caitlinmcmahon combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT jeffreysross combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient AT kareladicke combinationoftargetedtherapywithchemotherapybackboneinducesresponseinatreatmentresistanttriplenegativemcl1amplifiedmetastaticbreastcancerpatient |
_version_ |
1725959147931828224 |